File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation

TitleEBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation
Authors
KeywordsAllogeneic stem cell transplantation
Lymphoproliferative disorder
Epstein-Barr virus
Haploidentical
T-cell depletion
Issue Date2007
Citation
Pediatric Blood and Cancer, 2007, v. 49, n. 6, p. 869-872 How to Cite?
AbstractPost-transplant lymphoproliferative disease (PTLPD), due to the reactivation of Epstein-Barr virus (EBV), is a serious complication. The risk of the disorder increases with T-cell depletion methods, mismatched hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD), and immunosuppression. In contrast to solid organ transplantation, where EBV is typically of recipient origin, the source of the EBV in HSCT recipients is donor-derived B-lymphocytes. In this report, we describe a 15-year-old girl who underwent HSCT from her father as treatment for acute myeloid leukemia (AML). She subsequently developed disseminated PTLPD involving multiple organ and nodal sites. Her neoplastic lymphoblasts were host-derived and refractory to rituximab treatment due to lack of CD20 expression. © 2006 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/294422
ISSN
2023 Impact Factor: 2.4
2023 SCImago Journal Rankings: 0.992
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKasow, Kimberly A.-
dc.contributor.authorLeung, Wing-
dc.contributor.authorHorwitz, Edwin M.-
dc.contributor.authorWoodard, Paul-
dc.contributor.authorHandgretinger, Rupert-
dc.contributor.authorHale, Gregory A.-
dc.date.accessioned2020-12-03T08:22:42Z-
dc.date.available2020-12-03T08:22:42Z-
dc.date.issued2007-
dc.identifier.citationPediatric Blood and Cancer, 2007, v. 49, n. 6, p. 869-872-
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/294422-
dc.description.abstractPost-transplant lymphoproliferative disease (PTLPD), due to the reactivation of Epstein-Barr virus (EBV), is a serious complication. The risk of the disorder increases with T-cell depletion methods, mismatched hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD), and immunosuppression. In contrast to solid organ transplantation, where EBV is typically of recipient origin, the source of the EBV in HSCT recipients is donor-derived B-lymphocytes. In this report, we describe a 15-year-old girl who underwent HSCT from her father as treatment for acute myeloid leukemia (AML). She subsequently developed disseminated PTLPD involving multiple organ and nodal sites. Her neoplastic lymphoblasts were host-derived and refractory to rituximab treatment due to lack of CD20 expression. © 2006 Wiley-Liss, Inc.-
dc.languageeng-
dc.relation.ispartofPediatric Blood and Cancer-
dc.subjectAllogeneic stem cell transplantation-
dc.subjectLymphoproliferative disorder-
dc.subjectEpstein-Barr virus-
dc.subjectHaploidentical-
dc.subjectT-cell depletion-
dc.titleEBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/pbc.20710-
dc.identifier.pmid16421900-
dc.identifier.scopuseid_2-s2.0-34547743487-
dc.identifier.volume49-
dc.identifier.issue6-
dc.identifier.spage869-
dc.identifier.epage872-
dc.identifier.eissn1545-5017-
dc.identifier.isiWOS:000249881300025-
dc.identifier.issnl1545-5009-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats